Document is current
Any future updates will be listed below
-
Authors
Ntanasis-Stathopoulos, Ioannis https://orcid.org/0000-0002-6328-9783
Filippatos, Charalampos
Malandrakis, Panagiotis
Kastritis, Efstathios https://orcid.org/0000-0001-8191-5832
Terpos, Evangelos https://orcid.org/0000-0001-5133-1422
Dimopoulos, Meletios-Athanasios https://orcid.org/0000-0001-8990-3254
Gavriatopoulou, Maria https://orcid.org/0000-0002-6244-1229
- License Information
-
More Information
Article History
Received: 6 March 2025
Revised: 8 May 2025
Accepted: 19 May 2025
First Online: 26 May 2025
Competing interests
: INS declares honoraria from Janssen. PM declares honoraria from Janssen. EK declares honoraria from Amgen, Janssen, GSK, and Pfizer. ET declares honoraria from Amgen, Astra/Zeneca, Bristol Myers Squibb, Eusa Pharma, GSK, Integris Pharma, Janssen, Pfizer, Sanofi, and Takeda. MAD declares honoraria from Abbvie, Amgen, Bristol Myers Squibb, GSK, Janssen, Karyopharm, Pharmacyclics Inc, Pfizer, Sanofi, and Takeda. MG declares honoraria from GSK, Janssen, Sanofi, Abbvie, Amgen, and Takeda. The other authors declare no conflict of interest.
: An ethics approval was not required for this study as it is a systematic review and meta-analysis that synthesizes previously published, peer-reviewed data.
: Informed consent was not required for this study as it is a systematic review and meta-analysis that synthesizes previously published, peer-reviewed data.
